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Background
There have been no standard methods to predict the
hypersensitivity to cephalosporin. The relationship
between cephalosporin hypersensitivity and history of
beta-lactam hypersensitivity is not clear. This retrospec-
tive study is to evaluate the reliability of routine prophy-
lactic skin test with cefazolin in general population and
the relationship between results of cefazolin skin testing
and the history of beta-lactam hypersensitivity.
Methods
The medical records of patientswho underwent skin
testing to cefazolinfrom January 2010 to January 2011 at
Bundang Seoul National University Hospital, South
Korea were evaluated. Cefazolin was injected intrader-
maly with the concentration of 0.3 mg/ml without nega-
tive control. Skin testing to negative control was done
for some of the patients who showed the positive results
in cefazolin skin testing. History of beta-lactam hyper-
sensitivity is taken from the statements of patients.
Immediate adverse reactions after cefazolin injection
were evaluated by searching key words including urti-
caria, itching, hypersensitivity, or anaphylaxis within 3
days after start of cefazolin in electronic chart and
searching the consultations to allergy specialists or der-
matologists after cefazolin injection. And then the medi-
cal records of searched patients were reviewed by an
allergist.
Results
There were 13,153 cases of skin testing with cefazolin dur-
ing 13 months. Positive rate of cefazolin skin tests without
negative and positive controls was 1.4%. Among 81
patients with history of suspicious beta-lactam hypersensi-
tivity, 7 patients (9.9%) had positive results, as compared
with 176 patients (1.3%) of patients without suchhistory
(9.9% vs 1.3%, P < 0.0001). Among 19 patients who
showed positive skin testing to cefazolin and then tested
with negative control, 14 (73.4%) patients were proved as
false positive with reactivity to normal saline. Among
1,152 patientsexamined for skin testing to cefazolin more
than twice during 13 months, 21 patients (1.8%) showed
different results in serial skin tests to cefazolin.
Conclusions
This study suggests that routine prophylactic skin test-
ing to cefazolin without negative control for all patients
seems unreliable but prophylactic testing for patients
with the history of beta-lactam hypersensitivity could be
helpful, although the large prospective study is needed.
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